Passage Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
PASG Nasdaq 2836 www.passagebio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Passage Bio, Inc.

Remix to go public in reverse merger with once high-flying Passage Bio - Jun 25th, 2026 4:55 am
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - Jun 24th, 2026 7:43 pm
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Jun 24th, 2026 4:47 pm
Passage Bio and Remix Therapeutics Announce Merger Agreement - Jun 24th, 2026 2:05 pm
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside? - May 20th, 2026 6:35 am
Sector Update: Health Care Stocks Softer Late Afternoon - Apr 21st, 2026 1:57 pm
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says - Apr 21st, 2026 12:20 pm
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says - Apr 21st, 2026 9:46 am
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates - Apr 20th, 2026 5:00 am
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights - Mar 3rd, 2026 5:00 am
Passage Bio to Participate in Upcoming Investor Conferences - Feb 19th, 2026 5:00 am
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights - Nov 10th, 2025 2:15 pm